Trial Profile
A Phase I Study of R04929097 in Combination With Gemcitabine in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs RG 4733 (Primary) ; Gemcitabine
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 17 Jul 2013 Planned end date changed from 1 May 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 17 Jul 2013 Planned end date changed from 1 May 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 11 Apr 2013 Planned number of patients changed from 28 to 46 as reported by ClinicalTrials.gov.